Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660808 | 1.00 | ALOX5AP (0.46) | ALOX5APFEN1F2RL3EPHX2UCHL1 | |
| SCHEMBL4340518 | 1.00 | ALOX5AP (0.46) | ALOX5APFEN1F2RL3EPHX2UCHL1 | |
| SCHEMBL2543518 | 0.80 | ADRB2 (0.46) | ALOX5APFEN1F2RL3EPHX2UCHL1 | |
| SCHEMBL25249469 | 0.80 | CRBN (0.61) | — | |
| SCHEMBL2200755 | 0.79 | CHRNB4 (0.58) | ALOX5APFEN1F2RL3KDM1AOPRD1 | |
| SCHEMBL6293563 | 0.79 | F2RL3 (0.44) | ALOX5APFEN1F2RL3EPHX2UCHL1 | |
| SCHEMBL2539185 | 0.79 | F2RL3 (0.50) | ALOX5APFEN1F2RL3 | |
| SCHEMBL7997720 | 0.79 | F2RL3 (0.50) | ALOX5APFEN1F2RL3 | |
| SCHEMBL2200803 | 0.78 | ALOX5AP (0.50) | ALOX5APFEN1F2RL3OPRD1 | |
| SCHEMBL3113607 | 0.78 | DPP4 (0.52) | ALOX5APFEN1F2RL3KDM1AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536160-B2 | Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-09-17 | — | — | US | disclosed |
| EP-2004669-B1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA TAU IND FARMACEUTI (IT) | 2013-01-23 | — | — | EP | disclosed |
| US-20090275542-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-2004669-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007118830-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275542-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | ATP1A2, ATP6V1B1, ATP1A3 | ALOX5AP 2215/4885FEN1 3553/4885F2RL3 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.